A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma (RCC)

Interventions

DRUG: Pumitamig
DRUG: Ipilimumab
DRUG: Cabozantinib
DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]